Program
ontamalimab
Also written as “Ontamalimab”, “PF-00547659 SC Injection” and “PF-00547659 SC injection”.
Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Fatty Liver, led by Takeda.
Furthest: phase 3, since Aug 21, 201712 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 120 open or running | phase 3since Aug 21, 2017 | Jan 12, 2011 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 12, 2011First studies: 2 phase 2 studies in Crohn DiseaseFirst studyNCT01276509, NCT01298492
- Jun 13, 2012Phase 2 study in Colitis, UlcerativeNCT01620255 · 357 enrolled · United States, Australia, Austria and more
- Jan 8, 2013Phase 2 study in Colitis, UlcerativeNCT01771809 · 330 enrolled · United States, Australia, Austria and more
- Aug 21, 20172 phase 3 studies in Colitis, UlcerativeNCT03259334, NCT03259308
- Sep 6, 20172 phase 3 studiesNCT03290781, NCT03283085
- May 9, 20182 phase 3 studies in Crohn DiseaseNCT03566823, NCT03559517
- Jul 24, 2018Phase 3 study in Crohn DiseaseNCT03627091 · 40 enrolled · United States, Argentina, Australia and more
- Jun 30, 2025Phase 1 study in Fatty LiverNCT07052682 · 11 enrolled · United States
TargetBeta
MADCAM1 →read by rule
“Mucosal addressin cell adhesion molecule-1 inhibitor”ChEMBL 37, by rule
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07052682Fatty Liver · United States | 1 | Terminated | Dec 30, 2024 | 11 |
| NCT03627091Crohn Disease · United States, Argentina, Australia and more | 3 | Terminated | Jun 21, 2021 | 40 |
| NCT03566823Crohn Disease · United States, Argentina, Belgium and more | 3 | Terminated | Aug 18, 2020 | 34 |
| NCT03559517Crohn Disease · United States, Australia, Austria and more | 3 | Terminated | Jul 7, 2020 | 30 |
| NCT03283085Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Dec 13, 2023 | 557 |
| NCT03290781Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Jul 1, 2021 | 366 |
| NCT03259334Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Terminated | Jul 22, 2020 | 380 |
| NCT03259308Colitis, Ulcerative · United States, Argentina, Belgium and more | 3 | Terminated | Jul 15, 2020 | 279 |
| NCT01771809Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Dec 13, 2017 | 330 |
| NCT01620255Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Sep 22, 2014 | 357 |
| NCT01298492Crohn Disease · United States, Austria, Belgium and more | 2 | Completed | Jul 27, 2016 | 268 |
| NCT01276509Crohn Disease · United States, Austria, Belgium and more | 2 | Completed | Feb 7, 2014 | 265 |
How it is read
Names in the registry
- “Ontamalimab”, 7 entries
- “PF-00547659 SC Injection”, 4 entries
- “PF-00547659 SC injection”, 4 entries
- “25 mg Ontamalimab”, 1 entry
- “75 mg Ontamalimab”, 1 entry
Conditions, from the studies’ own filings
- Crohn Disease, 6 studies
- Colitis, Ulcerative, 5 studies
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.